Background
Methods
Study design and conduct
Patients
Immunosuppression
Evaluation
Statistical analysis
Results
Patient population and risk factors for diabetes
PTDM | No PTDMa | Pre-existing diabetes | No pre-existing diabetes | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
(a) ZEUS
| ||||||||||||
EVR (n = 14) | CsA (n = 8) | EVR (n = 128) | CsA (n = 125) | EVR (n = 13) | CsA (n = 12) | EVR (n = 142) | CsA (n = 133) | |||||
Recipient age at time of Tx (years) | 52.9 (10.7) | 57.4 (7.1) | 45.8 (12.0) | 45.1 (11.7) | 50.7 (6.3) | 56.2 (7.7)b | 46.5 (12.0) | 45.8 (11.8) | ||||
Male gender, n (%) | 10 (71.4) | 6 (75.0) | 82 (64.1) | 73 (58.4) | 10 (76.9) | 7 (58.3) | 92 (64.8) | 79 (59.4) | ||||
White recipient, n (%) | 14 (100.0) | 7 (87.5) | 126 (98.4) | 121 (96.8) | 12 (92.3) | 11 (91.7) | 140 (98.6) | 128 (96.2) | ||||
BMI (kg/m2) | ||||||||||||
Time of Tx | 27.4 (3.0) | 26.1 (3.4) | 25.1 (3.9) | 24.1 (3.9)c | 28.8 (3.7) | 26.9 (4.1) | 25.3 (3.9) | 24.2 (3.9)d | ||||
Time of RDN (month 4.5) | 26.9 (3.1) | 28.4 (5.6) | 25.7 (4.2) | 25.0 (4.1) | 29.1 (4.5) | 27.0 (4.2) | 25.8 (4.1) | 25.1 (4.1) | ||||
HCV+, n/N (%) | 1/13 (7.7) | 0/8 (0.0) | 3/127 (2.4) | 0/122 (0.0) | 0/13 (0.0) | 0/12 (0.0) | 4/140 (2.9) | 0/130 (0.0) | ||||
Random blood glucose, mmol/L | ||||||||||||
Time of Tx | 6.3 (1.7) | 6.6 (1.1) | 5.4 (1.3) | 5.1 (1.1) | 8.9 (3.3) | 9.3 (2.7) | 5.5 (1.3) | 5.2 (1.1) | ||||
Time of RDN (month 4.5) | 7.5 (3.9) | 5.6 (1.8) | 5.1 (1.0) | 5.2 (1.0) | 7.4 (3.2) | 7.7 (3.6) | 5.3 (1.3) | 5.2 (1.1) | ||||
I.V. treatment for rejection before RDN, n (%) | 4 (28.6) | 1 (12.5) | 12 (9.4) | 21 (16.8) | 2 (15.4) | 2 (16.7) | 17 (12.0) | 22 (16.5) | ||||
(b) HERAKLES
| ||||||||||||
EVR (n = 10) | CsA (n = 11) | EVR/reduced CsA (n = 9) | EVR (n = 142) | CsA (n = 131) | EVR/reduced CsA (n = 134) | EVR (n = 19) | CsA (n = 23) | EVR/reduced CsA (n = 18) | EVR (n = 152) | CsA (n = 142) | EVR/reduced CsA (n = 143) | |
Recipient age at Tx (years) | 49.4 (12.3) | 58.2 (6.9) | 51.7 (10.9) | 48.3 (12.6) | 48.7 (11.9) | 47.8 (12.6) | 58.2 (8.1) | 56.5 (9.7) | 57.5 (7.1) | 48.3 (12.5) | 49.4 (11.8) | 48.0 (12.5) |
Male gender, n (%) | 5 (50.0) | 4 (36.4) | 2 (22.2) | 84 (59.2) | 80 (61.1) | 84 (62.7) | 13 (68.4) | 16 (69.6) | 14 (77.8) | 89 (58.6) | 84 (59.2) | 86 (60.1) |
White recipient, n (%) | 10 (100.0) | 11 (100.0) | 9 (100.0) | 132 (93.0) | 126 (96.2) | 121 (90.3) | 16 (84.2) | 23 (100.0) | 17 (94.4) | 142 (93.4) | 137 (96.5) | 130 (90.9) |
BMI (kg/m2) | ||||||||||||
Time of Tx | 25.0 (3.4) | 28.2 (4.8) | 28.2 (6.1) | 24.9 (3.9) | 25.3 (4.0) | 25.4 (4.1) | 28.8 (5.6) | 30.2 (4.8) | 29.4 (4.3) | 24.9 (3.8) | 25.5 (4.2) | 25.5 (4.3) |
Time of RDN (month 3) | 25.3 (3.4) | 28.0 (4.5) | 29.3 (7.0) | 25.3 (3.6) | 25.4 (3.9) | 25.5 (4.3) | 28.7 (5.8) | 29.5 (5.1) | 29.2 (3.9) | 25.3 (3.6) | 25.6 (4.0) | 25.7 (4.6) |
HCV+, n/N (%) | – | – | – | 1 (0.7) | 3 (2.3) | 2 (1.5) | – | – | – | 1 (0.7) | 3 (2.1) | 2 (1.4) |
Random blood glucose (mmol/L) | ||||||||||||
Time of Tx | 5.3 (0.9) | 6.0 (1.4) | 5.8 (1.1) | 5.4 (1.1) | 5.2 (0.8) | 5.4 (1.2) | 6.4 (2.7) | 8.7 (3.6) | 6.0 (0.9) | 5.4 (1.1) | 5.2 (0.9) | 5.4 (1.2) |
Time of RDN (month 3) | 6.3 (1.7) | 5.8 (0.9) | 6.3 (2.4) | 5.3 (1.1) | 5.2 (1.1) | 5.2 (1.0) | 7.0 (2.4) | 7.6 (3.2) | 7.9 (4.1) | 5.4 (1.2) | 5.3 (1.1) | 5.3 (1.2) |
I.V. treatment for rejection before RDN, n (%) | – | 1 (9.1) | 2 (22.2) | 14 (9.9) | 7 (5.3) | 12 (9.0) | 4 (21.1) | 4 (17.4) | 1 (5.6) | 14 (9.2) | 8 (5.6) | 14 (9.8) |
Immunosuppression
PTDM | No PTDMa | Pre-existing diabetes | No pre-existing diabetes | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
(a) ZEUS
| ||||||||||||
EVR (n = 14) | CsA (n = 8) | EVR (n = 128) | CsA (n = 125) | EVR (n = 13) | CsA (n = 12) | EVR (n = 142) | CsA (n = 133) | |||||
Everolimus C0 (ng/mL) | ||||||||||||
RDNb | – | – | – | – | – | – | – | – | ||||
M12 | 6.2 (1.4) | – | 6.5 (2.1) | – | 7.7 (2.8) | – | 6.5 (2.0) | – | ||||
CsA C0 (ng/mL), mean (SD) | ||||||||||||
At RDN (month 3) | 158 (25) | 142 (38) | 153 (51) | 147 (50) | 138 (63) | 159 (40) | 154 (49) | 147 (50) | ||||
M12 | – | 141 (85) | – | 118 (33) | – | 130 (40) | – | 120 (37) | ||||
EC-MPS dose (mg/day), mean (SD) | ||||||||||||
RDN (month 3) | 1234 (366) | 1035 (449) | 1317 (284) | 1294 (289) | 1246 (431) | 1110 (419) | 1309 (293) | 1278 (305) | ||||
M12 | 1108 (452) | 1080 (465) | 1193 (363) | 1234 (340) | 1135 (385) | 1211 (333) | 1186 (371) | 1226 (347) | ||||
Oral steroids(mg/day) | ||||||||||||
BL to RDN (month 3) | 21.3 (5.1) | 16.3 (4.2)c | 17.7 (5.7) | 17.9 (5.7) | 18.1 (6.2) | 15.4 (4.8) | 18.1 (5.7) | 17.8 (5.6) | ||||
RDN to M12 | 10.7 (7.9) | 10.2 (3.2) | 7.6 (2.8) | 7.2 (4.3)c | 10.3 (10.9) | 6.3 (3.1) | 7.9 (3.7) | 7.4 (4.3)c | ||||
I.V. steroids to treat rejection, n (%) | ||||||||||||
BL to RDN (month 3) | 4 (28.6) | 1 (12.5) | 13 (10.2) | 21 (16.8) | 2 (15.4) | 2 (16.7) | 17 (12.0) | 22 (16.5) | ||||
RDN to M12 | 3 (21.4) | 1 (12.5) | 12 (9.4) | 11 (8.8) | 1 (7.7) | 2 (16.7) | 15 (10.6) | 12 (9.0) | ||||
(b) HERAKLES
| ||||||||||||
EVR (n = 10) | CsA (n = 11) | EVR/reduced CsA (n = 9) | EVR (n = 142) | CsA (n = 131) | EVR/reduced CsA (n = 134) | EVR (n = 19) | CsA (n = 23) | EVR/reduced CsA (n = 18) | EVR (n = 152) | CsA (n = 142) | EVR/reduced CsA (n = 143) | |
Everolimus C0 (ng/mL) | ||||||||||||
RDN (month 4.5) | 5.6 (3.0) | – | 4.5 (2.1) | 6.1 (3.2) | – | 7.0 (12.6) | 5.7 (2.1) |
–
| 6.1 (2.2) | 6.1 (3.1) | – | 6.8 (12.2) |
M12 | 7.2 (2.9) | – | 5.7 (2.4) | 6.6 (2.2) | – | 6.3 (2.7) | 7.2 (1.8) |
–
| 5.2 (2.2) | 6.6 (2.3) | – | 6.3 (2.7) |
CsA C0 (ng/mL) | ||||||||||||
RDN (month 4.5) | 155 (29) | 167 (48) | 157 (38) | 154 (46) | 164 (55) | 161 (72) | 169 (61) | 167 (50) | 157 (42) | 154 (45) | 164 (54) | 161 (70) |
M12 | – | 138 (56) | 126 (34) | – | 119 (29) | 80 (34) | – | 116 (36) | 59 (22) | – | 120 (32) | 83 (35) |
EC-MPS dose (mg/day) | ||||||||||||
RDN (month 4.5) | 1305 (268) | 1360 (240) | 1440 (0) | 1345 (246) | 1375 (214) | 1287 (314) | 1357 (216) | 1271 (288) | 1305 (413) | 1342 (246) | 1374 (215) | 1296 (307) |
M12 | 1183 (342) | 1280 (317) | – | 1171 (345) | 1266 (335) | – | 1260 (306) | 1239 (336) | – | 1172 (343) | 1267 (332) | – |
Oral steroids(mg/day) | ||||||||||||
BL to RDN (month 4.5) | 21.4 (4.4) | 19.7 (5.5)c | 20.9 (2.6) | 19.2 (5.6) | 19.2 (5.6) | 19.3 (5.3) | 16.6 (4.4) | 18.4 (5.4) | 18.8 (5.3) | 19.4 (5.0) | 19.3 (5.6) | 19.4 (5.2) |
RDN to M12 | 8.2 (3.4) | 7.4 (3.2) | 6.0 (2.7) | 7.4 (3.6) | 6.8 (3.7) | 6.9 (3.1) | 7.3 (4.0) | 7.1 (4.2) | 6.5 (1.7) | 7.4(3.6) | 6.9(3.6) | 6.9 (3.1) |
I.V. steroids to treat rejection, n (%) | ||||||||||||
BL to RDN (month 4.5) | 0 | 0 | 2 (22.2) | 12 (8.5) | 7 (5.3) | 11 (8.2) | 4 (21.1) | 1 (4.3) | 1 (5.6) | 12 (7.9) | 7 (4.9) | 13 (9.1) |
RDN to M12 | 1 (10.0) | 2 (18.2) | 1 (11.1) | 13 (9.2) | 10 (7.6) | 12 (9.0) | 4 (21.1) | 2 (8.7) | 1 (5.6) | 14 (9.2) | 12 (8.5) | 13 (9.1) |
Post-transplant diabetes mellitus
Pre-existing diabetes
Blood glucose concentrations
Biopsy-proven acute rejection
Renal function
(a) ZEUS study
| PTDM | No PTDMa | Pre-existing diabetes | No pre-existing diabetes | ||||||||
EVR (n = 14) | CsA (n = 8) | EVR (n = 128) | CsA (n = 125) | EVR (n = 13) | CsA (n = 12) | EVR (n = 142) | CsA (n = 133) | |||||
RDN (month 3) | 64.8 (13.8) | 54.3 (23.0) | 63.3 (17.6) | 63.0 (14.7) | 67.6 (22.4) | 64.4 (19.7) | 63.4 (17.2) | 62.5 (15.2) | ||||
P value vs CsAb | 0.31 | – | 0.92 | – | 0.50 | – | 0.85 | – | ||||
M12 | 78.5 (17.9) | 49.2 (16.3) | 70.4 (18.7) | 61.6 (16.1) | 73.1 (22.1) | 65.7 (22.2) | 71.1 (18.7) | 61.0 (16.2) | ||||
P value vs CsAb | 0.008 | – | < 0.001 | 0.22 | < 0.001 | – | ||||||
Change from RDN to M12 | 14.0 (11.4) | −9.2 (15.9) | 7.5 (10.5) | −1.5 (9.6) | 5.5 (5.9) | 0.7 (10.0) | 8.2 (10.8) | −1.8 (10.0) | ||||
P value vs CsAc | Not availabled | – | < 0.001 | – | 0.87 | – | < 0.001 | – | ||||
(b) HERAKLES study
| PTDM | No PTDMa | Pre-existing diabetes | No pre-existing diabetes | ||||||||
EVR (n = 10) | CsA (n = 11) | EVR/reduced CsA (n = 9) | EVR (n = 142) | CsA (n = 131) | EVR/reduced CsA (n = 134) | EVR (n = 19) | CsA (n = 23) | EVR/reduced CsA (n = 18) | EVR (n = 152) | CsA (n = 142) | EVR/reduced CsA (n = 143) | |
RND (month 4.5) | 70.6 (22.1) | 62.4 (16.7) | 59.4 (23.4) | 64.9 (14.6) | 61.2 (15.1) | 62.8 (14.1) | 71.3 (17.9) | 65.1 (13.6) | 67.6 (15.2) | 65.3 (15.2) | 61.3 (15.2) | 62.6 (14.8) |
P value vs CsAb | 0.34 | – | 0.81 | 0.05 | – | 0.39 | 0.41 | – | 0.59 | 0.03 | – | 0.43 |
M12 | 75.5 (29.9) | 60.5 (26.3) | 56.4 (28.1) | 70.8 (18.3) | 62.2 (16.1) | 63.1 (18.9) | 76.5 (20.8) | 65.5 (16.8) | 70.5 (19.8) | 71.1 (19.2) | 62.1 (17.0) | 62.7 (19.5) |
P value vs CsAb | 0.19 | – | 1.0 | < 0.001 | – | 0.61 | 0.11 | – | 0.50 | < 0.001 | – | 0.63 |
Change from RDN to M12 | 4.9 (16.7) | −1.9 (15.8) | −3.0 (10.1) | 5.9 (13.9) | 1.0 (11.1) | 0.4 (12.8) | 5.3 (12.9) | 2.8 (11.8) | 0.1 (11.7) | 5.8 (14.0) | 0.7 (11.5) | 0.1 (12.7) |
P value vs CsAc | 0.11 | – | 0.86 | < 0.001 | – | < 0.001 | 0.17 | – | 0.78 | < 0.001 | – | < 0.001 |